The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
Recommendations for the use of natriuretic peptides in acute cardiac care: A position statement from the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care
Abstract
Cardiac biomarkers are integral to the diagnosis and the treatment of acutely ill cardiac patients. The Working Group on Acute Cardiac Care of the European Society of Cardiology has established a Study Group to deal with issues related to cardiac biomarkers in this important area. Biomarkers are used to augment physician skill and judgment. Accordingly, we will outline principles for the application of biomarkers in acute cardiac care in a series of consensus documents; the first was on cardiac troponin (cTn).1 The present review is on natriuretic peptides (NPs) as markers of cardiac stress and heart failure (HF). Natriuretic peptides help diagnostically and provide prognostic information. Most data have been obtained with assays measuring B-type natriuretic peptide (BNP) or N-terminal proB-type natriuretic peptide (NT-proBNP); therefore, the review focuses on these two markers, and it will mention new markers at the end.2,3 The endocrine nature of the heart was first understood with the description of atrial natriuretic peptide (ANP),4 and later detection of brain (B-type) natriuretic peptide, that is, BNP,5,6 which is mainly released from the myocardium in humans.7 B-type natriuretic peptide has similar biological effects to ANP. Both are produced primarily in the atria under normal conditions.8 Atrial natriuretic peptide is mostly stored in atrial granules and thus available for ready release; BNP is stored to a limited extent. B-type natriuretic peptide requires de novo synthesis to be released in substantial amounts but the BNP gene responds rapidly.9 The atria contain the highest BNP and ANP concentrations in normals but this is shifted to the ventricles for BNP in HF.10 Natriuretic peptides promote natriuresis and diuresis, vasodilation, and antagonize the effects of the renin–angiotensin–aldosterone and sympathetic nervous systems (see Table 1).11 In the central nervous system, NPs act as neurotransmitters and decrease sympathetic tone, reduce secretion of arginine-vasopressin and corticotrophin, and inhibit salt appetite and water drinking.12 Natriuretic peptides modulate myocardial and vascular structure and function via antiproliferative and cytoprotective effects.9,11,13 Main physiological effects of natriuretic peptides Main physiological effects of natriuretic peptides Of the three known membrane bound natriuretic peptide receptors (NPRs), the guanylyl cyclase–coupled NPR–A and NPR–B receptors are responsible for most biological effects. Natriuretic peptide receptor–C is responsible for clearance and possibly regulation of cell proliferation. B-type natriuretic peptide exerts its activities via binding to NPR-A mediated by its second messenger, cyclic guanosine monophosphate, which regulates ion channels, protein kinases, and phosphodiesterases. In response to cardiac pathologies with pressure or volume overload, ventricular myocytes re-express foetal genes including ANP and BNP. Then, most of the BNP is released from the ventricles.8 NPs are increased in all oedematous disorders with salt and fluid overload and those with increased atrial or ventricular wall tension, e.g. in HF and renal failure9 (Table 2). Natriuretic peptides are quantitative markers related to the extent of left ventricular (LV) dysfunction and the severity of HF, although there is considerable overlap across functional classes. The predominant stimulus for release of BNP is end-diastolic wall stress.9,14–19 However, BNP is also increased in patients with atrial fibrillation due to atrial distension. In addition, myocardial ischaemia evokes BNP secretion,19,20 as do paracrine factors, such as angiotensin II, endothelin, and cytokines.13 B-type natriuretic peptide can also be secreted from myocardial fibroblasts.21 Diseases with increase in natriuretic peptides Diseases with increase in natriuretic peptides Our understanding of the biochemistry of BNP, its processing, and circulating proBNP-derived peptides is incomplete.14 The gene for BNP encodes a 134-amino acid preproBNP precursor. Removal of a 26-amino acid signal peptide gives rise to a 108-amino acid proBNP.15 Fragments of this signal peptide are present in blood of normals and patients with acute myocardial infarction (AMI).22 ProB-type natriuretic peptide is cleaved into BNP 1–32 and NT-proBNP 1–76 mainly upon secretion although some processed BNP is found in cardiomyocytes. Endoproteases and prohormone convertases, such as furin and corin, are involved in proBNP processing.16–18 B-type natriuretic peptide exhibits biological activity, but NT-proBNP has no and proBNP has little.23 There are only small amounts of intact BNP 1–32 in blood. ProB-type natriuretic peptide is the major immunoreactive form in patients with HF.24,25 Thus, HF is characterized by altered NP processing with secretion of less biologically active forms. This may explain the ‘NP paradox', where there are beneficial effects of administered BNP despite high concentrations of immmunoreactive NPs. N
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2015) · American Journal Of Pathology · doi:10.2353/ajpath · Cited by 4,908
Rapid Measurement of B-Type Natriuretic Peptide in the Emergency Diagnosis of Heart Failure
Maisel, A. S., Krishnaswamy, P., Nowak, R. M., McCord, J., Hollander, J. E., Duc, P., Omland, T., Storrow, A. B., Abraham, W. T., Wu, A. H. B., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020233 · Cited by 3,362
de Bold, A. J., Borenstein, H. B., Veress, A. T., & Sonnenberg, H. (1981) · Life Sciences · doi:10.1016/0024-3205(81)90370-2 · Cited by 3,148
Authors/Task Force Members, Dickstein, K., Cohen-Solal, A., Filippatos, G., McMurray, J. J. V., Ponikowski, P., Poole-Wilson, P. A., Stromberg, A., van Veldhuisen, D. J., Atar, D., et al. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn309 · Cited by 2,696
Self-citationEpstein, F. H., Levin, E. R., Gardner, D. G., & Samson, W. K. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807303390507 · Cited by 1,927
A new natriuretic peptide in porcine brain
Sudoh, T., Kangawa, K., Minamino, N., & Matsuo, H. (1988) · Nature · doi:10.1038/332078a0 · Cited by 1,816
Yasue, H., Yoshimura, M., Sumida, H., Kikuta, K., Kugiyama, K., Jougasaki, M., Ogawa, H., Okumura, K., Mukoyama, M., & Nakao, K. (1994) · Circulation · doi:10.1161/01.cir.90.1.195 · Cited by 1,333
The Prognostic Value of B-Type Natriuretic Peptide in Patients with Acute Coronary Syndromes
de Lemos, J. A., Morrow, D. A., Bentley, J. H., Omland, T., Sabatine, M. S., McCabe, C. H., Hall, C., Cannon, C. P., & Braunwald, E. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011053 · Cited by 1,284
The N-terminal Pro-BNP Investigation of Dyspnea in the Emergency department (PRIDE) study
Januzzi, J. L., Camargo, C. A., Anwaruddin, S., Baggish, A. L., Chen, A. A., Krauser, D. G., Tung, R., Cameron, R., Nagurney, J. T., Chae, C. U., et al. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.12.032 · Cited by 1,207
Januzzi, J. L., van Kimmenade, R., Lainchbury, J., Bayes-Genis, A., Ordonez-Llanos, J., Santalo-Bel, M., Pinto, Y. M., & Richards, M. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehi631 · Cited by 1,169
Cited by
Roffi, M., Patrono, C., Collet, J.-P., Mueller, C., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv320 · Cited by 8,261
Self-citation2023 ESC Guidelines for the management of acute coronary syndromes
Byrne, R. A., Rossello, X., Coughlan, J. J., Barbato, E., Berry, C., Chieffo, A., Claeys, M. J., Dan, G.-A., Dweck, M. R., Galbraith, M., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad191 · Cited by 5,333
Self-citationCollet, J.-P., Thiele, H., Barbato, E., Barthélémy, O., Bauersachs, J., Bhatt, D. L., Dendale, P., Dorobantu, M., Edvardsen, T., Folliguet, T., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa575 · Cited by 5,037
Self-citationHamm, C. W., Bassand, J.-P., Agewall, S., Bax, J., Boersma, E., Bueno, H., Caso, P., Dudek, D., Gielen, S., Huber, K., et al. (2012) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2011.11.006 · Cited by 1,068
Self-citationMueller, C., McDonald, K., de Boer, R. A., Maisel, A., Cleland, J. G. F., Kozhuharov, N., Coats, A. J. S., Metra, M., Mebazaa, A., Ruschitzka, F., et al. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1494 · Cited by 804
Self-citation
Metadata
- Authors
- Thygesen, K., Mair, J., Mueller, C., Huber, K., Weber, M., Plebani, M., Hasin, Y., Biasucci, L. M., Giannitsis, E., Lindahl, B., Koenig, W., Tubaro, M., Collinson, P., Katus, H., Galvani, M., Venge, P., Alpert, J. S., Hamm, C., & Jaffe, A. S.
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-02-02
- Volume
- 33
- Issue
- 16
- Pages
- 2001-2006
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W2169469834
- Cited by
- 273
- References
- 81
- FWCI
- 16.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recommendations for the use of natriuretic peptides in acute cardiac care: A position statement from the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care. https://app.cochat.ai/papers/10.1093/eurheartj/ehq509
- The paper
- Thygesen, K., Mair, J., Mueller, C., Huber, K., Weber, M., Plebani, M., Hasin, Y., Biasucci, L. M., Giannitsis, E., Lindahl, B., Koenig, W., Tubaro, M., Collinson, P., Katus, H., Galvani, M., Venge, P., Alpert, J. S., Hamm, C., & Jaffe, A. S. (2012). Recommendations for the use of natriuretic peptides in acute cardiac care: A position statement from the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care. European Heart Journal. https://doi.org/10.1093/eurheartj/ehq509
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.